79
Participants
Start Date
August 22, 2022
Primary Completion Date
June 30, 2024
Study Completion Date
December 31, 2024
TQB2450 injection
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents the binding of PD-L1 to PD-1 and B7.1 receptors on the surface of T cells, thereby reactivating T cells and enhancing the immune response.
Anlotinib Hydrochloride Capsule
Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
Carboplatin Injection
Carboplatin which s similar to alkylating agent, is a second-generation platinum anti-tumor drug, which mainly causes cross-linking of DNA within and between chains, destroys DNA molecules, and disintegrates the helix.
Paclitaxel Injection
Paclitaxel is a diterpene alkaloid with anticancer activity
Doxorubicin Hydrochloride Injection
Doxorubicin hydrochloride is a cycle non-specific anticancer chemotherapy drug, which directly acts on DNA, changes the nature of DNA template, and inhibits DNA polymerase.
Gemcitabine Hydrochloride Injection
Gemcitabine is a cell cycle specific antimetabolic drug, which mainly acts on tumor cells at the DNA synthesis stage.
Docetaxel injection
Docetaxel is an anti-tumor drug of paclitaxel, which plays an anti-tumor role by interfering with the microtubule network necessary for cell Mitosis and interphase cell function.
RECRUITING
Liaoning Cancer Hospital & Institute, Shenyang
RECRUITING
Obstetrics & Gynecology Hospital of Fudan University, Shanghai
RECRUITING
Taizhou People's Hospital, Taizhou
RECRUITING
Shandong Cancer Hospital, Jinan
RECRUITING
Yantai Yuhuangding Hospital, Yantai
RECRUITING
Linyi Cancer Hospital, Linyi
RECRUITING
TianJin Medical University Cancer Institute & Hopspital, Tianjin
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Zhongnan Hospital of Wuhan University, Wuhan
RECRUITING
Sun Yat-sen Memorial Hospital, Guangzhou
RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY